NCCN guidelines20 recommend AC (where A indicates doxorubicin, and C indicates cyclophosphamide) followed by biweekly or weekly paclitaxel as the preferred regimens for HER2-negative breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.